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The ovary is the major site of oestrogen production in
premenopausal women. Removal of the ovaries in pre-
menopausal patients with breast cancer has long been
recognised to potentially alter the course of disease. This
procedure leads to a marked reduction in the circulating
levels of oestrogen. It has been shown that ovariectomy
given as an adjuvant treatment reduces the odds of re-
currence or death by approximately 25%.
Goserelin and other luteinising hormone-releasing
hormone (LHRH) analogues produce reversible ovarian
suppression by downregulating gonadotropin release via
the LHRH receptors of the pituitary gland. Down-
regulated receptors lead to an inhibition of LH secre-
tion, which causes a blockade in ovarian function.
Currently, there are at least ﬁve diﬀerent kinds of
adjuvant treatment in premenopausal patients present-
ing with hormone-responsive tumours:
1. Chemotherapy
2. Tamoxifen
3. Ovarian ablation
4. LHRH analogue
5. LHRH analogue combined with tamoxifen
1. Chemotherapy
From a pooled analysis of 1115 premenopausal pa-
tients with oestrogen-receptor (ER) positive tumours,
the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) obtained data showing adjuvant chemo-
therapy applied alone induced a signiﬁcant 33%, and a
non-signiﬁcant 20%, risk reduction in the annual odds
of recurrence and death [1]. However, we do not yet
know whether anthracycline-containing regimens pro-
duce superior results in this setting.
There is currently little doubt that the eﬀect of adju-
vant chemotherapy is age-dependent. Thus, chemo-
therapy is much more eﬀective in premenopausal than in
postmenopausal women. The patient’s age plays a key
role for those experiencing amenorrhoea after chemo-
therapy, as younger women are less likely to become
permanently amenorrhoeic upon such treatment [2].
Several relevant trials and retrospective analyses have
speciﬁed that chemotherapy induces an outcome in pa-
tients undergoing amenorrhoea that is signiﬁcantly su-
perior to that shown by women who do not experience
an interruption of menses [3,4]. In particular, overall
prognosis is markedly increased in patients who expe-
rience chemotherapy-induced amenorrhoea. Cyclo-
phosphamide, methotrexate and ﬂuorouracil- (CMF)
and ﬂuorouracil, doxorubicin, and cyclophosphamide-
(FAC) or taxane-containing regimens induce amenor-
rhoea in 60–70% and 30–50% of patients, respectively.
2. Tamoxifen
There is no direct comparison between tamoxifen and
polychemotherapy in premenopausal patients with hor-
mone-responsive breast cancer. The EBCTCG overview
of randomised trials with tamoxifen has shown that the
administration of 5 years of tamoxifen in patients
younger than 50 years of age leads to a relative risk
reduction in the annual odds of recurrence of approxi-
mately 45% and in the odds of death of approximately
32% [5]. Although the number of subjects randomised in
these studies amounted to no more than 1327, tamoxifen
can safely be stated to have at least an eﬀect equal to
polychemotherapy in inducing a reduction in recur-
rence. Furthermore, investigations have suggested ta-
moxifen is signiﬁcantly active in reducing mortality, an
eﬀect which is lacking for polychemotherapy. However,
ﬁnal conclusions are still to be drawn as to whether
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tamoxifen is indeed as eﬀective as adjuvant polyche-
motherapy in the premenopausal setting.
3. Ovarian ablation
Among the currently available therapies for pre-
menopausal early-stage breast cancer, ovarian ablation,
together with aromatase inhibition, is applied to de-
crease oestrogen production.
The EBCTCG 1996 overview included a total of 2102
women under 50 years of age who had participated in a
series of randomised trials investigating ovarian ablation
applied alone in early breast cancer [6]. ER status was
known in such studies – totalling 993 patients – inves-
tigating this treatment modality plus cytotoxic chemo-
therapy versus the same chemotherapy. The results of
these trials clearly indicate that ovarian ablation signif-
icantly reduced the annual odds of death and recurrence
regardless of patients’ nodal status. However, ovarian
ablation showed no activity in the presence of adjuvant
chemotherapy.
Two trials have directly compared chemotherapy and
ovarian ablation with patient numbers totalling over
1000 [7,8]. Neither investigation showed a signiﬁcant
diﬀerence between the two randomised groups. Am-
enorrhoea occurred in 68% of the patients receiving 3-
weekly CMF. These two trials unmistakably indicate
that permanent surgery- or radiotherapy-induced ovar-
ian ablation has signiﬁcant activity – comparable to that
produced with CMF-based chemotherapy – in patients
with hormone-responsive tumours.
4. LHRH analogue
LHRH analogues have been shown to be eﬀective
treatment for advanced breast cancer, providing a sim-
ilar clinical beneﬁt to surgical oophorectomy in terms of
progression-free survival (PFS) and overall survival
(OS) [9,10]. Thus, they appear to be ideal tools to induce
a hormone proﬁle of – reversible – castration without
surgical or radio-therapeutic interventions.
Two clinical trials of diﬀerent maturity have
compared CMF-based chemotherapy with LHRH ana-
logues given for 2 years. The Zoladex Early Breast
Cancer Research Association (ZEBRA) trial rando-
mised more than 1600 patients to receive either 2 years
of goserelin or 6 cycles of CMF [11]. OS rates were
absolutely identical in the presence of ER-positive dis-
ease. However, in patients with receptor-negative tu-
mours, CMF was shown to be signiﬁcantly superior to
goserelin in terms of survival. This leads to the conclu-
sion that the eﬃcacy of endocrine treatment is restricted
to patients with hormone-responsive tumours. Second,
the Takeda Adjuvant Breast cancer study with Leu-
prorelin Acetate (TABLE) compared an LHRH ana-
logue with CMF in 600 premenopausal patients with
hormone-responsive, node-positive breast cancer [12].
At 3 years follow-up, the TABLE trial evidenced no
signiﬁcant diﬀerence between the two arms under in-
vestigation, but there was a signiﬁcantly lower amount
of serious adverse events in the endocrine treatment
group.
The results of these two investigations clearly indicate
that induction of amenorrhoea by the administration of
LHRH analogues in approximately 2000 premenopau-
sal patients with hormone-responsive tumours has ef-
fects that are comparable to those of CMF-based
chemotherapy in terms of recurrence-free survival
(RFS).
5. LHRH analogue combined with tamoxifen
In advanced breast cancer, combination endocrine
treatment with an LHRH analogue plus tamoxifen has
been shown to be superior to treatment with either
LHRH or tamoxifen alone, as measured by the ob-
jective response rate, median PFS and OS [13].
In the adjuvant setting, the Austrian Breast &
Colorectal Cancer Study Group (ABCSG) Trial 5
compared a combination of LHRH analogue and ta-
moxifen with CMF [14]. More than 1000 premeno-
pausal patients with hormone-responsive tumours
were randomised between 6 cycles of CMF intrave-
nously (i.v.) and combination endocrine treatment
consisting of 3 years goserelin and 5 years tamoxifen.
After 6 years of follow-up, patients receiving combi-
nation endocrine treatment showed signiﬁcantly better
RFS rates than those treated with CMF. Conversely,
other trials with similar designs have indicated no
diﬀerence between patients given chemotherapy and
those receiving a combination of LHRH analogue and
tamoxifen [15,16].
Finally, another ongoing multicentre, randomised
investigation in Austria, ABCSG Trial 12, is currently
investigating whether the combination of goserelin and
anastrozole is superior to goserelin plus tamoxifen.
More than 1000 patients have been randomised so far.
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